Should patients with advanced HIV disease be started on INSTI-based regimens?
What do the latest clinical data show about giving rifampin with dolutegravir, bictegravir, or tenofovir alafenamide?
In this downloadable audio of a live Webinar, Chloe Orkin, MBChB, FRCP, MD, provides a rapid update on the clinical impact of new data reported at the Boston meeting.
Expert faculty members summarize key studies from this important annual conference.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.